Engineered Phagemids for Nonlytic, Targeted Antibacterial Therapies
Name
Engineered Phagemids for Nonlytic Targeted Antibacterial Therapies-Collins.pdf
Size
146.56 KB
Format
Adobe PDF
Checksum (MD5)
5cd4ac36cd9702ac671a680353810ff9
Author(s)
Krom, Russell-John
Saluja, Prerna
Lobritz, Michael Andrew
Collins, James J.
Date Issued
July 2015
Journal
Nano Letters
Publisher
American Chemical Society (ACS)
Citation
Krom, Russell J.; Bhargava, Prerna; Lobritz, Michael A. and Collins, James J. “Engineered Phagemids for Nonlytic, Targeted Antibacterial Therapies.” Nano Letters 15, no. 7 (July 2015): 4808–4813. © 2015 American Chemical Society
Version
Author's final manuscript
Abstract
The increasing incidence of antibiotic-resistant bacterial infections is creating a global public health threat. Because conventional antibiotic drug discovery has failed to keep pace with the rise of resistance, a growing need exists to develop novel antibacterial methodologies. Replication-competent bacteriophages have been utilized in a limited fashion to treat bacterial infections. However, this approach can result in the release of harmful endotoxins, leading to untoward side effects. Here, we engineer bacterial phagemids to express antimicrobial peptides (AMPs) and protein toxins that disrupt intracellular processes, leading to rapid, nonlytic bacterial death. We show that this approach is highly modular, enabling one to readily alter the number and type of AMPs and toxins encoded by the phagemids. Furthermore, we demonstrate the effectiveness of engineered phagemids in an in vivo murine peritonitis infection model. This work shows that targeted, engineered phagemid therapy can serve as a viable, nonantibiotic means to treat bacterial infections, while avoiding the health issues inherent to lytic and replicative bacteriophage use.
MIT Department
Institute for Medical Engineering and Science
MIT Synthetic Biology Center
Broad Institute of MIT and Harvard
Massachusetts Institute of Technology. Department of Biological Engineering
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1021/acs.nanolett.5b01943
